[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Cyclobenzaprine.]
[M03AB01, succinylcholine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Succinylcholine.]
[N05AL01, sulpiride, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Sulthiame.]
[N06DA01, tacrine, The metabolism of Cyclobenzaprine can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The metabolism of Cyclobenzaprine can be decreased when combined with Tamoxifen.]
[N05CD07, temazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Temazepam.]
[L01CB02, teniposide, Teniposide may increase the neurotoxic activities of Cyclobenzaprine.]
[S01HA03, tetracaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lurasidone.]
[A04AD10, dronabinol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Apomorphine.]
[L04AX02, thalidomide, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Cyclobenzaprine.]
[R03DA04, theophylline, The metabolism of Cyclobenzaprine can be decreased when combined with Theophylline.]
[P02CA02, thiabendazole, The metabolism of Cyclobenzaprine can be decreased when combined with Thiabendazole.]
[R06AD03, thiethylperazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Thiethylperazine.]
[N05CA19, thiopental, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Thiothixene.]
[N05AL03, tiapride, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Cyclobenzaprine can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tilidine.]
[M03BX04, tolperisone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome and seizure can be increased when Cyclobenzaprine is combined with Tramadol.]
[N06AF04, tranylcypromine, Cyclobenzaprine may increase the serotonergic activities of Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Cyclobenzaprine.]
[C03DB02, triamterene, The metabolism of Cyclobenzaprine can be decreased when combined with Triamterene.]
[N05CD05, triazolam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Triazolam.]
[A03AB12, mepenzolate, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Trifluperidol.]
[N05AA05, triflupromazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Triflupromazine.]
[N04AA01, trihexyphenidyl, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Trimethadione.]
[N06AA06, trimipramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Triprolidine.]
[A03BB01, butylscopolamine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Cyclobenzaprine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tryptophan.]
[M03AA02, tubocurarine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tubocurarine.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Cyclobenzaprine.]
[L02BX03, abiraterone, The serum concentration of Cyclobenzaprine can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Cyclobenzaprine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Cyclobenzaprine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Cyclobenzaprine can be decreased when combined with Telaprevir.]
[N03AX21, ezogabine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ezogabine.]
[C08DA01, verapamil, The metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Viloxazine.]
[L01CA02, vincristine, Vincristine may increase the neurotoxic activities of Cyclobenzaprine.]
[B01AA03, warfarin, The metabolism of Cyclobenzaprine can be decreased when combined with Warfarin.]
[N05AF05, zuclopenthixol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Cyclobenzaprine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Levetiracetam.]
[L01EC01, vemurafenib, The serum concentration of Cyclobenzaprine can be increased when it is combined with Vemurafenib.]
[L01ED01, crizotinib, The metabolism of Cyclobenzaprine can be decreased when combined with Crizotinib.]
[J01MA13, trovafloxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ziprasidone.]
[G04BD07, tolterodine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[L03AB11, peginterferon alfa-2a, The metabolism of Cyclobenzaprine can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The metabolism of Cyclobenzaprine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Atracurium.]
[S01FA01, atropine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Cyclobenzaprine.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Cyclobenzaprine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Cyclobenzaprine.]
[M03BX01, baclofen, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Baclofen.]
[A08AA11, lorcaserin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lorcaserin.]
[V03AX03, cobicistat, The metabolism of Cyclobenzaprine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Cyclobenzaprine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Enzalutamide.]
[L04AA31, teriflunomide, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Teriflunomide.]
[N05CA04, barbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Cyclobenzaprine can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Cyclobenzaprine.]
[S01GA07, brimonidine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Brimonidine.]
[N04BD02, rasagiline, Cyclobenzaprine may increase the serotonergic activities of Rasagiline.]
[A03FA09, mosapride, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Donepezil.]
[N03AX22, perampanel, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Perampanel.]
[N02CC03, zolmitriptan, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Diethyl ether.]
[L04AX06, pomalidomide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pomalidomide.]
[N05AD07, benperidol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Benperidol.]
[J01MA15, gemifloxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Cyclobenzaprine can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Benzocaine.]
[N02CC02, naratriptan, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Naratriptan.]
[N04AC01, benztropine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Levomilnacipran.]
[N06AX26, vortioxetine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Cyclobenzaprine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The metabolism of Cyclobenzaprine can be decreased when combined with Dapagliflozin.]
[N05CH03, tasimelteon, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Cyclobenzaprine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Cyclobenzaprine can be increased when combined with Apremilast.]
[S01ED02, betaxolol, The metabolism of Cyclobenzaprine can be decreased when combined with Betaxolol.]
[L04AC11, siltuximab, The metabolism of Cyclobenzaprine can be increased when combined with Siltuximab.]
[A03BA03, hyoscyamine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Cyclobenzaprine.]
[L01XH04, belinostat, The metabolism of Cyclobenzaprine can be increased when combined with Belinostat.]
[N01AX05, alfaxalone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Alfaxalone.]
[D11AA01, glycopyrronium, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Acepromazine.]
[A06AH03, naloxegol, The risk or severity of respiratory depression can be increased when Naloxegol is combined with Cyclobenzaprine.]
[N04AA02, biperiden, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Cyclobenzaprine.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dicoumarol.]
[N06AX11, mirtazapine, Cyclobenzaprine may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Cyclobenzaprine can be increased when combined with Secukinumab.]
[N02BE01, acetaminophen, The metabolism of Cyclobenzaprine can be decreased when combined with Acetaminophen.]
[A03AA09, difemerine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tioclomarol.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Cyclobenzaprine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cariprazine.]
[S01EC01, acetazolamide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Acetophenazine.]
[J02AC05, isavuconazole, The metabolism of Cyclobenzaprine can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Osimertinib.]
[N05CA05, aprobarbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Aprobarbital.]
[N03AX23, brivaracetam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Cyclobenzaprine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dexbrompheniramine.]
[N06AA19, amineptin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Amineptine.]
[N05AX17, pimavanserin, Cyclobenzaprine may increase the neurotoxic activities of Pimavanserin.]
[N06BX11, aniracetam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Aniracetam.]
[A05AA04, obeticholic acid, The metabolism of Cyclobenzaprine can be decreased when combined with Obeticholic acid.]
[N01BB01, bupivacaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Bupivacaine.]
[N07BC01, buprenorphine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Buspirone.]
[N02AF01, butorphanol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Butorphanol.]
[S01GX07, azelastine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Cyclobenzaprine can be increased when combined with Rucaparib.]
[L01EF02, ribociclib, The metabolism of Cyclobenzaprine can be decreased when combined with Ribociclib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Cyclobenzaprine.]
[N02BF02, pregabalin, The therapeutic efficacy of Cyclobenzaprine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Beclamide.]
[N06BC01, caffeine, The metabolism of Cyclobenzaprine can be decreased when combined with Caffeine.]
[S01HA02, benoxinate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Oxybuprocaine.]
[J01XX08, linezolid, Cyclobenzaprine may increase the serotonergic activities of Linezolid.]
[J05AE09, tipranavir, The metabolism of Cyclobenzaprine can be decreased when combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Cyclobenzaprine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Cyclobenzaprine can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Cyclobenzaprine may increase the serotonergic activities of Safinamide.]
[L01XX59, enasidenib, The metabolism of Cyclobenzaprine can be decreased when combined with Enasidenib.]
[A02BX12, bismuth subnitrate, Cyclobenzaprine may increase the neurotoxic activities of Bismuth subnitrate.]
[J05AG03, efavirenz, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Efavirenz.]
[N04AA11, bornaprine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Brotizolam.]
[N05CA03, butobarbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Butriptyline.]
[N01BX04, capsaicin, The metabolism of Cyclobenzaprine can be increased when combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Vinylbital.]
[L02BB05, apalutamide, The metabolism of Cyclobenzaprine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Carbamazepine.]
[A03AA03, camylofine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Cyclobenzaprine.]
[N03AX24, cannabidiol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cannabidiol.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Cyclobenzaprine.]
[L01XX62, ivosidenib, The metabolism of Cyclobenzaprine can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cetirizine.]
[N05CM04, carbromal, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Cyclobenzaprine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyclobenzaprine.]
[R03BB08, revefenacin, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Cyclobenzaprine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Cyclobenzaprine can be decreased when combined with Carmustine.]
[L01EX13, gilteritinib, The therapeutic efficacy of Cyclobenzaprine can be decreased when used in combination with Gilteritinib.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Cyclobenzaprine is combined with Amifampridine.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Cyclobenzaprine.]
[A03FA08, cinitapride, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Cyclobenzaprine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Cyclobenzaprine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Clobazam.]
[N05BA22, cloxazolam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cloxazolam.]
[L04AB01, etanercept, The metabolism of Cyclobenzaprine can be increased when combined with Etanercept.]
[N05AA06, cyamemazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cyamemazine.]
[S01AA13, fusidic acid, The metabolism of Cyclobenzaprine can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The metabolism of Cyclobenzaprine can be decreased when combined with Pipemidic acid.]
[N07XX11, pitolisant, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Cyclobenzaprine.]
[G04BE04, yohimbine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The metabolism of Cyclobenzaprine can be increased when combined with Insulin pork.]
[S01EX02, dapiprazole, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dapiprazole.]
[N02CC08, lasmiditan, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lasmiditan.]
[N03AX25, cenobamate, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Cyclobenzaprine can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dexbrompheniramine.]
[N02AX03, dezocine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Cyclobenzaprine can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Cyclobenzaprine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Cyclobenzaprine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Cyclobenzaprine.]
[A07DA04, difenoxin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Eletriptan.]
[M01AH02, rofecoxib, The metabolism of Cyclobenzaprine can be decreased when combined with Rofecoxib.]
[C01BD07, dronedarone, The metabolism of Cyclobenzaprine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Chlordiazepoxide.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Cyclobenzaprine.]
[A03AA08, dihexyverine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The metabolism of Cyclobenzaprine can be decreased when combined with Capmatinib.]
[G04BD09, trospium, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dyclonine.]
[N05CD14, remimazolam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Remimazolam.]
[N07XX04, sodium oxybate, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Cyclobenzaprine is combined with Oliceridine.]
[D01AE07, chlorphenesin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Chlorphenesin.]
[R06AB04, chlorpheniramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Chlorzoxazone.]
[N05BX03, etifoxine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Etifoxine.]
[N06BX18, vinpocetine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ethyl loflazepate.]
[B06AC06, berotralstat, The metabolism of Cyclobenzaprine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Cyclobenzaprine can be decreased when combined with Lonafarnib.]
[L01FX21, naxitamab, Cyclobenzaprine may increase the neurotoxic activities of Naxitamab.]
[P03AX07, abametapir, The serum concentration of Cyclobenzaprine can be increased when it is combined with Abametapir.]
[V03AF12, trilaciclib, The metabolism of Cyclobenzaprine can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Felbamate.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Cyclobenzaprine.]
[J01MB07, flumequine, The metabolism of Cyclobenzaprine can be decreased when combined with Flumequine.]
[N01AB05, trichloroethylene, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Cyclobenzaprine can be increased when it is combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Cyclobenzaprine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Gabapentin.]
[N07CA02, cinnarizine, The metabolism of Cyclobenzaprine can be decreased when combined with Cinnarizine.]
[J01MB06, cinoxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Cyclobenzaprine can be increased when combined with Somapacitan.]
[P01CA03, fexinidazole, The metabolism of Cyclobenzaprine can be decreased when combined with Fexinidazole.]
[H01AC09, lonapegsomatropin, The metabolism of Cyclobenzaprine can be increased when combined with Lonapegsomatropin.]
[R06AA04, clemastine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Cyclobenzaprine can be decreased when combined with Mefenamic acid.]
[J01FF01, clindamycin, Cyclobenzaprine may increase the neurotoxic activities of Clindamycin.]
[N06AX25, St. John's wort extract, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Cyclobenzaprine.]
[N01BB10, levobupivacaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The metabolism of Cyclobenzaprine can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Cyclobenzaprine.]
[C01EB24, mavacamten, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Mavacamten.]
[N05AH06, clothiapine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Clozapine.]
[N05BA13, halazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Halazepam.]
[H01AC08, somatrogon, The metabolism of Cyclobenzaprine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Cyclobenzaprine may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Cyclobenzaprine can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Hexafluronium.]
[A03AB10, hexocyclium, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ifenprodil.]
[J01FA15, telithromycin, The metabolism of Cyclobenzaprine can be decreased when combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Desloratadine.]
[N02CC05, almotriptan, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Almotriptan.]
[J02AC02, itraconazole, The metabolism of Cyclobenzaprine can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, The metabolism of Cyclobenzaprine can be decreased when combined with Acyclovir.]
[N05BA10, ketazolam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ketazolam.]
[L01EA01, imatinib, The metabolism of Cyclobenzaprine can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Cyclobenzaprine can be decreased when combined with Posaconazole.]
[N03AX09, lamotrigine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Levocabastine.]
[N07BC04, lofexidine, The therapeutic efficacy of Cyclobenzaprine can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The metabolism of Lomefloxacin can be decreased when combined with Cyclobenzaprine.]
[N05CD06, lormetazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lormetazepam.]
[A03AA04, mebeverine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Medifoxamine.]
[N04AA03, methixene, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Cyclobenzaprine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cyclobarbital.]
[N05AD03, metylperon, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Melperone.]
[L01AA01, cyclophosphamide, Cyclophosphamide may increase the neurotoxic activities of Cyclobenzaprine.]
[N06AX07, minaprine, Cyclobenzaprine may increase the serotonergic activities of Minaprine.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Cyclobenzaprine.]
[S01XA18, cyclosporine, The metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Cyclobenzaprine may increase the serotonergic activities of Moclobemide.]
[N06BA07, modafinil, The metabolism of Cyclobenzaprine can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cyproheptadine.]
[C03XA02, conivaptan, The metabolism of Cyclobenzaprine can be decreased when combined with Conivaptan.]
[J05AF10, entecavir, The metabolism of Cyclobenzaprine can be decreased when combined with Entecavir.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Cyclobenzaprine.]
[L01AX04, dacarbazine, The metabolism of Cyclobenzaprine can be decreased when combined with Dacarbazine.]
[G03XA01, danazol, The metabolism of Cyclobenzaprine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Deanol.]
[A04AD11, nabilone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Nabilone.]
[M01AX01, nabumetone, The metabolism of Cyclobenzaprine can be decreased when combined with Nabumetone.]
[N05BA16, nordazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Nordazepam.]
[N06AX06, nefazodone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Niaprazine.]
[N03AG06, tiagabine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tiagabine.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Cyclobenzaprine.]
[M03AC11, cisatracurium, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cisatracurium.]
[R05DA06, normethadone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Escitalopram.]
[G04BD08, solifenacin, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Desipramine.]
[N03AF02, oxcarbazepine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Cyclobenzaprine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Oxiracetam.]
[N04AA08, dexetimide, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Cyclobenzaprine.]
[A03AA01, oxyphencyclimine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Cyclobenzaprine can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Cyclobenzaprine.]
[R05DA09, dextromethorphan, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Cyclobenzaprine can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Diamorphine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Cyclobenzaprine.]
[N05BA01, diazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Phenacemide.]
[N03AD02, phensuximide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Cyclobenzaprine can be decreased when combined with Diclofenac.]
[A03AA07, dicyclomine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may increase the neurotoxic activities of Cyclobenzaprine.]
[N05AD05, pipamperone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pipamperone.]
[A03AB14, pipenzolate, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Cyclobenzaprine can be decreased when combined with Erlotinib.]
[A08AA03, diethylpropion, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Diethylpropion.]
[C08CA03, isradipine, The metabolism of Cyclobenzaprine can be decreased when combined with Isradipine.]
[A03AB11, poldine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C02DB01, dihydralazine, The metabolism of Cyclobenzaprine can be decreased when combined with Dihydralazine.]
[N02CA01, dihydroergotamine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Hydromorphone.]
[J05AE08, atazanavir, The metabolism of Cyclobenzaprine can be decreased when combined with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Cyclobenzaprine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pridinol.]
[R06AB03, dimethindene, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Progabide.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Cyclobenzaprine.]
[S01HA04, proparacaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Cyclobenzaprine.]
[R06AA02, diphenhydramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cisapride.]
[N05AL04, remoxipride, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Remoxipride.]
[C01BA03, disopyramide, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Cyclobenzaprine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Cyclobenzaprine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ropivacaine.]
[J01MB01, rosoxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Rosoxacin.]
[A04AD12, aprepitant, The metabolism of Cyclobenzaprine can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The metabolism of Cyclobenzaprine can be decreased when combined with Bortezomib.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Cyclobenzaprine.]
[N06AA16, dothiepin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Doxepin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.]
[N06AB06, sertraline, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Droperidol.]
[A08AA10, sibutramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Sibutramine.]
[N05AL02, sultopride, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Sumatriptan.]
[J01MA05, temafloxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Cyclobenzaprine can be decreased when combined with Terbinafine.]
[M03BX07, tetrazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Thiopropazate.]
[G04BD01, emepronium, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Emepronium.]
[N06AX14, tianeptine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tofisopam.]
[N06AG03, toloxatone, Cyclobenzaprine may increase the serotonergic activities of Toloxatone.]
[N03AX11, topiramate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Topiramate.]
[N05CD11, triazulenone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Triclofos.]
[A03AB08, tridihexethyl, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Trimethobenzamide.]
[N04AA12, tropatepine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Enflurane.]
[C02CA06, urapidil, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Urapidil.]
[J01MA04, enoxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Veralipride.]
[L01CA04, vinorelbine, Vinorelbine may increase the neurotoxic activities of Cyclobenzaprine.]
[S01GX10, epinastine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Cyclobenzaprine can be decreased when combined with Barnidipine.]
[N05CF02, zolpidem, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Moricizine.]
[G02AB03, ergonovine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Cyclobenzaprine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Estazolam.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Cyclobenzaprine.]
[G03CA03, estradiol, The metabolism of Cyclobenzaprine can be decreased when combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Cyclobenzaprine can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Cyclobenzaprine can be decreased when combined with Ethambutol.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Cyclobenzaprine is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ethchlorvynol.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Cyclobenzaprine.]
[N04AA05, profenamine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ethotoin.]
[N01BX01, ethyl chloride, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ethyl chloride.]
[S01XA06, ethylmorphine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ethylmorphine.]
[N01AX07, etomidate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Etomidate.]
[L01CB01, etoposide, The metabolism of Cyclobenzaprine can be decreased when combined with Etoposide.]
[N05AE03, sertindole, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Sertindole.]
[R06AX12, terfenadine, The metabolism of Cyclobenzaprine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Cyclobenzaprine.]
[N06AB08, fluvoxamine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Cyclobenzaprine.]
[A02BA03, famotidine, The metabolism of Cyclobenzaprine can be decreased when combined with Famotidine.]
[P02CA03, albendazole, The metabolism of Cyclobenzaprine can be increased when combined with Albendazole.]
[N03AX26, fenfluramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Fenfluramine.]
[N02AB03, fentanyl, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Fentanyl.]
[G04BD02, flavoxate, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Cyclobenzaprine.]
[J02AC01, fluconazole, The metabolism of Cyclobenzaprine can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Melitracen.]
[V03AZ01, ethanol, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The metabolism of Cyclobenzaprine can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Flurazepam.]
[N05AG01, fluspirilene, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Cyclobenzaprine can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Cyclobenzaprine.]
[M03AA01, alcuronium, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Alcuronium.]
[G01AX06, furazolidone, Cyclobenzaprine may increase the serotonergic activities of Furazolidone.]
[J05AE10, darunavir, The metabolism of Cyclobenzaprine can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Amisulpride.]
[M03AC02, gallamine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Gallamine.]
[N03AA04, barbexaclone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Cyclobenzaprine can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Cyclobenzaprine.]
[N04BC06, cabergoline, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cabergoline.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Cyclobenzaprine.]
[N03AD03, methsuximide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Alfentanil.]
[N05CM18, dexmedetomidine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Glutethimide.]
[L01EX02, sorafenib, The metabolism of Cyclobenzaprine can be decreased when combined with Sorafenib.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluindione.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Halothane.]
[N05AH04, quetiapine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Allobarbital.]
[N05CA16, hexobarbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Cyclobenzaprine can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Cyclobenzaprine can be decreased when combined with Nilvadipine.]
[R05DA03, hydrocodone, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[G04BD06, propiverine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.]
[B05CB02, sodium citrate, Cyclobenzaprine may increase the neurotoxic activities of Sodium citrate.]
[H01AC02, somatrem, The metabolism of Cyclobenzaprine can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Imipramine.]
[L01CD01, paclitaxel, Cyclobenzaprine may increase the neurotoxic activities of Paclitaxel.]
[M03BX02, tizanidine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tizanidine.]
[L03AB04, interferon alfa-2a, The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Milnacipran.]
[A03AA30, piperidolate, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Alprazolam.]
[N05CH02, ramelteon, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ramelteon.]
[R06AE01, buclizine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[L01XX35, anagrelide, The metabolism of Cyclobenzaprine can be decreased when combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Alprenolol.]
[L03AB09, interferon alfacon-1, The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfacon-1.]
[J05AF04, stavudine, Stavudine may increase the neurotoxic activities of Cyclobenzaprine.]
[N06AA13, iprindole, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Iprindole.]
[N06AF05, iproniazid, Cyclobenzaprine may increase the serotonergic activities of Iproniazid.]
[J05AB13, penciclovir, The metabolism of Cyclobenzaprine can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, Cyclobenzaprine may increase the serotonergic activities of Isocarboxazid.]
[N01AB06, isoflurane, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Isoflurane.]
[N04BX02, entacapone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Cyclobenzaprine can be decreased when combined with Isoniazid.]
[N06AX18, reboxetine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Reboxetine.]
[H01AC01, somatropin, The metabolism of Cyclobenzaprine can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Cyclobenzaprine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Cyclobenzaprine can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Cyclobenzaprine can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Olanzapine.]
[V03AC03, deferasirox, The serum concentration of Cyclobenzaprine can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Cyclobenzaprine can be increased when combined with Abatacept.]
[N04BC09, rotigotine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Rotigotine.]
[J01MB02, nalidixic acid, The metabolism of Cyclobenzaprine can be decreased when combined with Nalidixic acid.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Cyclobenzaprine.]
[N03AX18, lacosamide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lacosamide.]
[N04BA01, levodopa, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lidocaine.]
[J01FF02, lincomycin, Cyclobenzaprine may increase the neurotoxic activities of Lincomycin.]
[N06BA13, armodafinil, The metabolism of Cyclobenzaprine can be increased when combined with Armodafinil.]
[N02CA07, lisuride, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lorazepam.]
[C10AA02, lovastatin, The metabolism of Cyclobenzaprine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Loxapine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Cyclobenzaprine can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Cyclobenzaprine can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Maprotiline.]
[A08AA05, mazindol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Mazindol.]
[R06AE05, meclizine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Meclizine.]
[N05BA03, medazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Medazepam.]
[N05CH01, melatonin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Melatonin.]
[N02AB02, meperidine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Meperidine.]
[M03BX06, mephenesin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Mephenesin.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Cyclobenzaprine is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Mephenytoin.]
[N03AA01, mephobarbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Cyclobenzaprine.]
[N06BA03, methamphetamine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Metamfetamine.]
[A03AB07, methantheline, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Metharbital.]
[G02CB05, metergoline, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Cyclobenzaprine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Cyclobenzaprine can be decreased when combined with Pemetrexed.]
[M03BA03, methocarbamol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methocarbamol.]
[N05CA15, methohexital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methohexital.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Ziconotide.]
[N05AA02, methotrimeprazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Cyclobenzaprine can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methoxyflurane.]
[V04CG05, methylene blue, Cyclobenzaprine may increase the serotonergic activities of Methylene blue.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Cyclobenzaprine.]
[N03AF03, rufinamide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Rufinamide.]
[N05CE02, methyprylon, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Cyclobenzaprine.]
[C01BB02, mexiletine, The metabolism of Cyclobenzaprine can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Cyclobenzaprine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Cyclobenzaprine.]
[N05CD08, midazolam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Midazolam.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.]
[L01XX23, mitotane, The metabolism of Cyclobenzaprine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Cyclobenzaprine is combined with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Molindone.]
[C01BD01, amiodarone, The metabolism of Cyclobenzaprine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Amitriptyline.]
[N02AA01, morphine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Cyclobenzaprine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Cyclobenzaprine.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Cyclobenzaprine.]
[M03AC03, vecuronium, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Amobarbital.]
[N06AA17, amoxapine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Amoxapine.]
[N03AB05, fosphenytoin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Cyclobenzaprine can be decreased when combined with Interferon beta-1b.]
[N04BC04, ropinirole, Cyclobenzaprine may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The metabolism of Cyclobenzaprine can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Cyclobenzaprine can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Cyclobenzaprine.]
[L04AC03, anakinra, The metabolism of Cyclobenzaprine can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Cyclobenzaprine.]
[M02AA12, naproxen, The metabolism of Cyclobenzaprine can be decreased when combined with Naproxen.]
[N06AX21, duloxetine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Tolcapone.]
[S03AA01, neomycin, Cyclobenzaprine may increase the neurotoxic activities of Neomycin.]
[N01AH06, remifentanil, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Remifentanil.]
[N05AX14, iloperidone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Desvenlafaxine.]
[N06AF02, nialamide, Cyclobenzaprine may increase the serotonergic activities of Nialamide.]
[C08CA04, nicardipine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[P02DA01, niclosamide, The metabolism of Cyclobenzaprine can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Cyclobenzaprine.]
[N05CD02, nitrazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Nitrazepam.]
[N05CF03, zaleplon, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Zaleplon.]
[N04BC05, pramipexole, Cyclobenzaprine may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Nomifensine.]
[S01AE02, norfloxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Norfloxacin.]
[N06AA10, nortriptyline, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Nortriptyline.]
[L03AB07, interferon beta-1a, The metabolism of Cyclobenzaprine can be decreased when combined with Interferon beta-1a.]
[L04AC04, rilonacept, The metabolism of Cyclobenzaprine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Cyclobenzaprine can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Opipramol.]
[N02AA02, opium, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Opium.]
[N05BA04, oxazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Oxazepam.]
[C07AA02, oxprenolol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Oxypertine.]
[A03AB03, oxyphenonium, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.]
[M03AC01, pancuronium, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pancuronium.]
[N05CC05, paraldehyde, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Paraldehyde.]
[C02KC01, pargyline, Cyclobenzaprine may increase the serotonergic activities of Pargyline.]
[J01MA03, pefloxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Pefloxacin.]
[G04BD11, fesoterodine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pentobarbital.]
[C04AD03, pentoxifylline, The metabolism of Cyclobenzaprine can be decreased when combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pergolide.]
[N05AB03, perphenazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Cyclobenzaprine.]
[N02AD02, phenazocine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Phenazocine.]
[N06AF03, phenelzine, Cyclobenzaprine may increase the serotonergic activities of Phenelzine.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenindione.]
[N03AA02, phenobarbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Cyclobenzaprine.]
[S01GA05, phenylephrine, The metabolism of Cyclobenzaprine can be increased when combined with Phenylephrine.]
[N03AB02, phenytoin, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Cyclobenzaprine can be increased when combined with Golimumab.]
[C08CX01, mibefradil, The metabolism of Cyclobenzaprine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pindolol.]
[J05AE01, saquinavir, The metabolism of Cyclobenzaprine can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pipotiazine.]
[A02BX03, pirenzepine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Piritramide.]
[J01MA11, grepafloxacin, The metabolism of Cyclobenzaprine can be decreased when combined with Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Cyclobenzaprine can be decreased when combined with Delavirdine.]
[N05CA22, proxibarbal, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Cyclobenzaprine can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Cyclobenzaprine may increase the neurotoxic activities of Polymyxin B.]
[J05AE03, ritonavir, The serum concentration of Cyclobenzaprine can be increased when it is combined with Ritonavir.]
[N05BA11, prazepam, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Cyclobenzaprine.]
[N01BB04, prilocaine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Cyclobenzaprine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Primidone.]
[S01HA05, procaine, Cyclobenzaprine may increase the serotonergic activities of Procaine.]
[L01XB01, procarbazine, Cyclobenzaprine may increase the serotonergic activities of Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Prochlorperazine.]
[N04AA04, procyclidine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Cyclobenzaprine can be decreased when combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Propanidid.]
[A03AB05, propantheline, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Propiomazine.]
[N01AX10, propofol, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Propofol.]
[N02AC04, propoxyphene, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Cyclobenzaprine can be decreased when combined with Propranolol.]
[N02CC04, rizatriptan, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Rizatriptan.]
[N06AA11, protriptyline, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Cyclobenzaprine.]
[N05AX12, aripiprazole, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Aripiprazole.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Cyclobenzaprine is combined with Dalfampridine.]
[A03AB15, diphemanil, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Talbutal.]
[N05CA09, vinbarbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Mepyramine.]
[C01BA01, quinidine, The metabolism of Cyclobenzaprine can be decreased when combined with Quinidine.]
[P01BC01, quinine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Cyclobenzaprine can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Cyclobenzaprine can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Oxitriptan.]
[S01FA02, scopolamine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Scopolamine.]
[N05CA06, secobarbital, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Secobarbital.]
[N04BD01, selegiline, Cyclobenzaprine may increase the serotonergic activities of Selegiline.]
[N03AG01, valproic acid, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Valproic acid.]
[R03BB01, ipratropium bromide, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
